Author

Michael W. Meshad

Observed names: M Meshad, M W Meshad, M. Meshad, Michael Meshad, Michael W. Meshad, MD

Observed institutions: Louisiana State University, Emory University, Vanderbilt University, Providence Hospital, Sarah Cannon, Vanderbilt-Ingram Cancer Center, Universidad Central de Venezuela

OpenAlex ID: A5042717041

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

2020 · M.C. Liu, G.R. Oxnard, et al. · Annals of Oncology · 1,506

PDF

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

2019 · Paul G Richardson, Albert Oriol, et al. · The Lancet Oncology · 388

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)

2021 · Lori J. Goldstein, Mauro Mansutti, et al. · Breast Cancer Research and Treatment · 101

PDF

Treatment of advanced squamous cell carcinoma of the head and neck with cisplatin, bleomycin, and methotrexate (PBM).

1981 · T J Ervin, R Weichselbaum, et al. · PubMed · 72

Efficacy of Oral Ondansetron, A Selective Antagonist of 5-HT3 Receptors, in the Treatment of Nausea and Vomiting Associated with Cyclophosphamide-Based Chemotherapies

1994 · Luigi X. Cubeddu, Kelly Pendergrass, et al. · American Journal of Clinical Oncology · 42

Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)

2024 · Nicholas Turner, Cristina Saura, et al. · Journal of Clinical Oncology · 40

PDF

Oral Ondansetron 8 mg Twice Daily is as Effective as 8 mg Three Times Daily in the Prevention of Nausea and Vomiting Associated with Moderately Emetogenic Cancer Chemotherapy

1997 · Thomas M. Beck, Martin York, et al. · Cancer Investigation · 19

Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy.

1992 · W R Berry, K W House, et al. · PubMed · 17

Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience.

1996 · D M Paul, A M Garrett, et al. · PubMed · 13

Chemotherapy for Advanced Carcinoma of the Head and Neck: A Clinical Update

1981 · T. J. Ervin, D. Miller, et al. · Archives of Otolaryngology - Head and Neck Surgery · 12

Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study.

2023 · Makenzi Colleen Evangelist, James Edward Butrynski, et al. · Journal of Clinical Oncology · 10

PDF

Paclitaxel, 5-Fluorouracil, and Leucovorin (TFL) in the Treatment of Metastatic BreastCancer

2000 · Brenda P. Nicholson, David M. Paul, et al. · Clinical Breast Cancer · 9

Biomarker testing in early-stage NSCLC: Results from the MYLUNG Consortium.

2024 · Makenzi Colleen Evangelist, James Edward Butrynski, et al. · Journal of Clinical Oncology · 4

P60.13 MYLUNG Consortium: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network. Pragmatic Prospective RWR Study

2021 · M. Evangelist, R. Jotte, et al. · Journal of Thoracic Oncology · 1

Efficacy, safety, and cytokine profiling with addition of the toll-like receptor (TLR) 7/8 dual agonist EIK1001 to standard of care (SOC) first-line (1L) therapy: The phase 2 TeLuRide-005 trial in stage 4 NSCLC.

2026 · Bo Wang, Rajesh Naidu Kukunoor, et al. · Journal of Clinical Oncology

Testing and treatment patterns in KRAS mutant mNSCLC: Results from the MYLUNG Consortium.

2025 · Bo Wang, Makenzi Colleen Evangelist, et al. · Journal of Clinical Oncology

PDF

Impact of an Oncology Clinical Pharmacist Intervention on Clinical Trial Enrollment in The US Oncology Network’s MYLUNG Consortium

2024 · Elizabeth Koselke, PharmD, BCOP, Lisa C. Kaspin-Powell, PhD, et al. · Journal of the Advanced Practitioner in Oncology

PDF

Clinical activity and safety of naptumomab estafenatox (NAP) and docetaxel in patients (pts) with checkpoint inhibitor (CPI) –pretreated advanced/metastatic non-small cell lung cancer (NSCLC): Preliminary results of a P2 trial.

2024 · Timothy Larson, Robert M. Jotte, et al. · Journal of Clinical Oncology

Impact of oncology clinical pharmacist intervention on clinical trial enrollment in The U.S. Oncology Network’s MYLUNG Consortium.

2022 · Elizabeth Koselke, Shannon Hough, et al. · Journal of Clinical Oncology

Works count: 19

Citation count: 2,234

H-index: 10

I10-index: 11